Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/6/2024 | $5.00 → $2.00 | Neutral → Sell | Goldman |
1/31/2024 | Outperform → Market Perform | TD Cowen | |
1/31/2024 | $5.00 → $18.00 | Market Perform → Outperform | Leerink Partners |
10/30/2023 | $6.00 | Outperform → Market Perform | Leerink Partners |
10/12/2023 | $13.00 | Buy | Citigroup |
9/13/2023 | $5.00 | Buy → Neutral | Goldman |
9/12/2023 | Buy → Neutral | Guggenheim | |
7/28/2023 | $25.00 → $13.00 | Overweight → Equal-Weight | Morgan Stanley |
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
Goldman downgraded 2seventy bio from Neutral to Sell and set a new price target of $2.00 from $5.00 previously
TD Cowen downgraded 2seventy bio from Outperform to Market Perform
Leerink Partners upgraded 2seventy bio from Market Perform to Outperform and set a new price target of $18.00 from $5.00 previously
Abecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in KarMMa-9 study results in over $80 million in anticipated cost savings over the next several years 24% reduction in operating expenses versus the second quarter reflects continued progress on streamlining 2seventy's cost structure; third quarter net loss of approximately $10 million Ended quarter with approximately $192 million in cash, cash equivalents, and marketable securities; expected cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for
2seventy bio, Inc. (NASDAQ:TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the financial results conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It's recommended that participants join 10 minutes prior to the event's start. Members of the management team will also be presenting at the following upcoming investor conference: Guggenheim's Inaugural H
Following regulatory approval in the earlier line setting this quarter, Abecma generated $54 million U.S. commercial revenue and saw meaningful growth in demand Recent completion of Hemophilia A and gene editing technology sale to Novo Nordisk for up to $40 million reinforces exclusive focus on Abecma with streamlined cost structure Approximately $28 million (43%) quarter-on-quarter reduction in operating expenses due to completion of sale of R&D business to Regeneron on April 1, 2024 Ended quarter with approximately $202 million cash, cash equivalents, and marketable securities; cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today re
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)
SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)
SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)
8-K - 2seventy bio, Inc. (0001860782) (Filer)
8-K - 2seventy bio, Inc. (0001860782) (Filer)
10-Q - 2seventy bio, Inc. (0001860782) (Filer)
Abecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in KarMMa-9 study results in over $80 million in anticipated cost savings over the next several years 24% reduction in operating expenses versus the second quarter reflects continued progress on streamlining 2seventy's cost structure; third quarter net loss of approximately $10 million Ended quarter with approximately $192 million in cash, cash equivalents, and marketable securities; expected cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for
2seventy bio, Inc. (NASDAQ:TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the financial results conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It's recommended that participants join 10 minutes prior to the event's start. Members of the management team will also be presenting at the following upcoming investor conference: Guggenheim's Inaugural H
2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study Decision results in over $80 million in anticipated cost savings for 2seventy over the next several years and accelerates path to breakeven in 2025 Expanded 3L+ label drives re-acceleration in Abecma U.S. revenues with third quarter revenue expected to grow approximately 30% from second quarter revenue of $54 million 2seventy bio, Inc. (NASDAQ:TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidom
On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:NVO). Under the terms, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for autoimmune disease. The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology. Related: FDA Approves Bristol-Myers/2seventy Bio’s Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer. The program is based on the original research a
Wedbush analyst David Nierengarten reiterates 2seventy bio (NASDAQ:TSVT) with a Neutral and maintains $5 price target.
2seventy bio, Inc. (NASDAQ:TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company's Board of Directors (the "Board"), effective immediately. Casdin Capital owns approximately 2.3% of 2seventy bio's outstanding shares as of 03/20/24. "We are pleased to welcome Eli and Charlie to the 2seventy Board," said Dan Lynch, chair of the Board of Directors. "Eli is a highly regarded, leading life sciences and healthcare investor and has a deep understanding of and history with the Company. Charlie has a track record of helping compan
Believes 2seventy Could Be Conservatively Worth ~$9 Per Share if the Company Exclusively Focuses on Its Most-Valuable Asset Abecma, Reduces Corporate Overhead and Makes Improvements to the Composition of the Management Team and Board Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (NASDAQ:TSVT) ("2seventy" or the "Company") outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the "Board"). *** December 6, 2023 2seventy bio, Inc. 60 Binney Street Cambridge, MA 02142 Attention: Board of Directors Dear Members of the Board: Engine Capital LP (together with its affiliates, "Engine" or "we"), is a meaningful shareh
O'Callaghan, a well-regarded life-science business leader with global experience and a significant track record of success, joins as part of plan to evolve Deep Genomics as a forward-integrated biopharmaceutical company Founder and current CEO Brendan Frey, Ph.D., F.R.S.C. to assume new role of chief innovation officer, remain a member of the board and bolster plans for further technology development and innovation, leveraging artificial intelligence (AI) to decode RNA biology for novel drug development Lead independent director Chip Baird appointed as chair of the board Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines